Results 141 to 150 of about 70,860 (294)

Hybrid closed‐loop insulin delivery improves glycaemic control compared with sensor‐augmented pump therapy: A meta‐analysis of ‘free‐living’ randomised trials in type 1 diabetes

open access: yesDiabetic Medicine, EarlyView.
Abstract Aim Although hybrid closed‐loop systems (HCLS) and sensor‐augmented pump (SAP) therapy are advanced diabetes management technologies for type 1 diabetes, their relative efficacy in optimising glycaemic control is not fully established. This meta‐analysis evaluated the impact of HCLS versus SAP therapy on glucose regulation across multiple ...
Amardeep S. Sidki   +3 more
wiley   +1 more source

Diabetes mellitus and associated factors, determined by glycated hemoglobin [PDF]

open access: bronze, 2020
Déborah Carvalho Malta   +9 more
openalex   +1 more source

Prognostic models for all‐cause and cardiovascular mortality in type 2 diabetes: Systematic review

open access: yesDiabetic Medicine, EarlyView.
Abstract Aims The elevated risk of all‐cause and cardiovascular mortality in individuals with type 2 diabetes mellitus (T2DM) has led to growing efforts to develop prognostic models for early identification of high‐risk individuals. This systematic review synthesised existing models to inform future model development, enhance predictive performance and
Monica Kundu   +10 more
wiley   +1 more source

Impact of screening programmes for type 1 diabetes in youth: A systematic review and meta‐analysis

open access: yesDiabetic Medicine, EarlyView.
Abstract Aim To evaluate the impact of anti‐islet antibody (IAb) screening on the general population and first‐degree relatives (FDRs)/high‐risk individuals and evidence‐based follow‐up modalities. Methods We performed this review through systematic searches of PubMed, EMBASE, Cochrane Library, Web of Science, ClinicalTrials.gov and International ...
Roberto Franceschi   +24 more
wiley   +1 more source

Efficacy and safety of CT‐868, a novel, fully biased, dual glucagon‐like peptide‐1/glucose‐dependent insulinotropic polypeptide receptor agonist, in type 2 diabetes: A double‐blind, randomized placebo controlled phase 2 trial

open access: yesDiabetes, Obesity and Metabolism, EarlyView.
Abstract Aims To assess the glycaemic efficacy and safety of CT‐868, a cAMP signal‐biased, dual glucagon‐like peptide‐1/glucose‐dependent insulinotropic polypeptide receptor agonist, in participants with type 2 diabetes (T2D). Materials and Methods This 26‐week (W), phase 2, randomized, double‐blind placebo‐controlled trial enrolled adults with T2D ...
Manu V. Chakravarthy   +10 more
wiley   +1 more source

Burden of long‐term conditions and management of people with overweight and obesity: Data from the United Kingdom primary care cohort of the IMPACT‐O study

open access: yesDiabetes, Obesity and Metabolism, EarlyView.
Abstract Aims The multi‐country epIdeMiology landscape PAtient Care paThways of Obesity (IMPACT‐O) retrospective cohort study utilised existing electronic medical records to gather data on overweight and obesity. We report UK data on obesity‐related complications (ORCs) and management strategies.
Kamlesh Khunti   +6 more
wiley   +1 more source

Work productivity, associated risk factors and costs on presenteeism and absenteeism in Chinese patients with young‐onset type‐2 diabetes in Hong Kong

open access: yesDiabetes, Obesity and Metabolism, EarlyView.
Abstract Aims Those with young‐onset type‐2 diabetes (YOD), diagnosed before age of 40 years, experience heightened risk of complications. The economic burden extends beyond medical costs, impacting work productivity. Materials and Methods Chinese patients with YOD were recruited between June 2023 and April 2024 in the Precision Medicine to redefine ...
Juliana N. M. Lui   +14 more
wiley   +1 more source

Trend of Changes in Blood Sugar and Glycated Hemoglobin in Electronic Health Records, Sari, Iran 2012- 2018

open access: green, 2020
Dariush Ghasemi-Semeskandeh   +4 more
openalex   +1 more source

Home - About - Disclaimer - Privacy